Acute promyelocytic leukemia (APL) represents a subtype of acute myeloid leukemia with characteristic morphologie, molecular, and immunophenotypic features. Previous immunophenotypic analyses hâve shown that leukemic cells in APL typically
Acute promyelocytic leukemia (APL) is perhaps the foremost example of a leukemia in which the correct diagnosis is necessary for appropriate treatment. The highly spécifie t( 15; 17)(q22;ql 1-21) translocation, seen in the majority of cases, fuses the 5' portion of the PML (promyelocytic leukemia) gène on chromosome 15 with the 3' portion of the retinoic acid receptor-CX (RARA) gène on chromosome 17 and générâtes a PML-RARA fusion protein. 1_3 This fusion confers the exquisite sensitivity of this tumor to differentiation by all-fraws-retinoic acid (ATRA). 4 Treatment of APL with ATRA has short-and long-term benefits 5 - 6 and, as a resuit, has become a mainstay of therapy for APL. More recently, arsenic trioxide has been identified as a potential alternative therapeutic agent in relapsed APL. 7 For thèse reasons, accurate diagnosis of APL is critical.
The diagnosis of APL relies on the synthesis of spécifie morphologie, molecular, and immunophenotypic features. The French-American-British (FAB) criteria categorize APL into 2 subtypes: M3 (hypergranular) and M3v (microgranular variant). 8 -9 While M3 morphologie features are highly characteristic, the morphologie features of M3v are less spécifie, and this subtype may be difficult to diagnose. 10 In most cases, the diagnosis ultimately is confirmed by identification of the t(15;17) translocation using standard cytogenetics or fluorescence in situ hybridization (FISH)," 12 by identification ofthe PML-RARA fusion using reverse transcriptase-polymerase chain reaction (RT-PCR), or both. [13] [14] [15] The typical turnaround times for thèse methods and their lack of availability at some institutions may preclude rapid confirmation of the diagnosis, resulting in a greater initial dependence on morphologie and immunophenotypic features. 
Materials and Methods

Patients
Seventeen patients diagnosed with APL at the Hospital of the University of Pennsylvania, Philadelphia, between 1985 and 1995 form the basis of this study. Ail cases met FAB criteria for APL or showed évidence of the t(15;17) by cytogenetic analysis or by molecular methods (FISH or RT-PCR). FAB subclassifications were confirmed by review of Wright-stained peripheral blood or bone marrow aspirate smears, bone marrow core biopsy spécimens, and cytochemistry stains of blood or bone marrow (Sudan black B, myeloperoxidase, nonspecific [a-naphthyl butyratej esterase, and periodic acid-Schiff). Ail cases were classified as acute myeloid leukemia (AML)-M3 (10) or AMLM3v (6) by FAB criteria, except for 1 leukemia originally classified as AML-M2 based on morphologie features and cytochemical stains. In the light of finding a t( 15; 17) translocation, this case was reclassified as AML-M3v.
Flow Cytometry (Immunophenotyping)
The leukemic cells were analyzed with antibodies directed against CD34 (HPCA-2), HLA-DR, CD33, CD13, CD2, CD4, CD7, and, in sélect cases, CD38 (Leu-17). Cells from peripheral blood or bone marrow were purified by Ficoll-Hypaque gradient and stained according to the manufacturer's protocol. Antibodies were obtained from Immunotech, Westbrook, ME (CD34) and Becton Dickinson, San José, CA (ail others), and were fluorescently labeled with phycoerythrin or fluorescein isothiocyanate. Gated populations of leukemic cells were selected based on forward and side scatter properties, which varied depending on the degree of granularity of a particular tumor. Samples were analyzed on a FACSort flow cytometer (Becton Dickinson) using CellQuest software (Becton Dickinson). Ten thousand events were analyzed for each surface marker.
Cell Sorting
Tumor samples from peripheral blood of patients 1 and 16 were stained with CD34 alone or with CD34 and CD38. Cells were incubated with murine anti-human CD34 conjugated with phycoerythrin (Becton Dickinson) and murine anti-human CD38 conjugated with fluorescein isothiocyanate (Becton Dickinson) or Cy-chrome (Pharmingen, San Diego, CA) in staining buffer (phosphate-buffered saline + 10% fetal calf sérum) on ice for 30 turer's protocol. Slides were counterstained with 4'6-diamidino-2-phenylindole dichloride for visualization with a triple bandpass filter on a Nikon (Rockville, MD) Optiphot II fluorescence microscope, and selected images were digitized using Cytovision (Applied Imaging, Santa Clara, CA). Sorti ng directly onto Cell-TAK-coated slides proved to be the most successful method of collecting and retaining very small numbers of sorted cells for FISH. For ail FISH experiments, a nucleus was scored as positive if the red and green signais were fused, were touching, or were separated by less than 1 signal width. Scoring was performed in a blinded fashion to eliminate bias.
RNA Extraction and RT-PCR
Mononuclear cells were separated from bone marrow and peripheral blood by using Lymphocyte Séparation Media (Organon Teknika, Durham, NC), and RNA was extracted using RNAzol Reagent (TEL-Test, Friendswood, TX) according to the manufacturera protocol. Complementary DNA (cDNA) was synthesized from 1 u.g of total RNA using 200 ng of a reverse transcription-specific primer (NRTR) for PML-RARA, 5-TCACCTTGTTGAT-GATGCAGT-3'; or for p 2 PCR was performed (PE9600, Perkin Elmer Cetus, Emeryville, CA) using 2 separate sets of nested primers to detect the différent PML-RARA fusion cDNAs. For the intron 3 breakpoint, first-round PCR primers were NPML, 5-TACCAGCGCGACTACGAGGAGAT-3' (sensé) and NRTR (same as previous) (antisense). Second-round (nested) primers were ALOC, 5-GATGAAGTGCTACGC-CTCGGA-3' (sensé) and AJL, 5 -ATGTTCTTCTGGAT-GCTGCGG-3' (antisense). For the intron 6 and exon 6 breakpoints, first-round PCR primers were PMLVI, 5'-GCCCCAGGAAGGTCATCAAGA-3' (sensé) and NRTR (same as previous) (antisense). Second-round (nested) primers were PMLVII, 5-TCTGAGGAGGGGAAG-GAGGCA-3' (sensé) and AJL (same as previous) (antisense). The integrity of the RNA préparation was confirmed in ail samples by the présence of P 2 -microglobulin messenger RNA using 5-ACTCAGGTCATCCAGCAGA-GAATG-3' (sensé) and 5'-CATCAAACATGGAGAACA-GCAC-3' (antisense) as PCR primers.
The PCR mixture contained 3 p.L of cDNA, lx PCR buffer with a 1.5-mmol/L concentration of magnésium chloride (Perkin-Elmer), a 200-u.mol/L concentration of deoxynucleotide triphosphate (Pharmacia, Piscataway, NJ), 5% dimethyl sulfoxide, and 1.5 U of Taq polymerase (Perkin-Elmer) in a final volume of 50 uX. PCR was performed with initial denaturation at 95°C for 5 minutes followed by 30 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds, with a final 72°C 5-minute extension. A 1 -p.L aliquot of the primary product was used as the template for the second round of PCR, which proceeded for 35 cycles using the same amplification conditions, with primers as described. PCR products were visualized by UV light following electrophoresis through an ethidium bromide-containing agarose gel.
Results
APL May Be a CD34
+ Leukemia 
CD34+ APL Shows Variable Degrees of Myeloid Progenitor Cell Differentiation
Analysis of coexpression of CD34 and CD38 was used to détermine the degree of myeloid progenitor cell Figure 2D is an example of a CD34" case, shown for comparison. As demonstrated, the level of differentiation of the leukemic cells varies considerably; case 1 (Figure 2A ) shows a prédominant, less mature CD34 + CD38" population with a smaller, more differentiated CD34 + CD38 + population, whereas case 2 ( Figure   2C ) exemplifies a more differentiated leukemia with a prédominant CD34 + CD38 + population. Case 8 ( Figure   2D ) is the most differentiated tumor, as shown by the lack of CD34 expression and the prédominant CD38 positivity. Thus, similar to other subtypes of AML, APL may show variable levels of myeloid differentiation. • nuclei examined in both populations from the patients with APL showed the t(15;17) translocation, confirming that both the primitive CD34 + CD38" and the more committed CD34 + CD38 + progenitor populations are part of the leukemic clone.
•
Primitive Progenitor Populations Are Part of the Leukemic Clone in APL
The background level of positivity in the négative control (acute biphenotypic leukemia) ranged from 9.2% to 11.0%.
Immunophenotypic Corrélations
CD34 status was correlated with FAB classifications of M3 or M3v. Of 7 M3v cases, 5 (71%) were CD34+, whereas only 2 (20%) of 10 cases of classic M 3 were CD34 + ,
suggesting an association between expression of CD34 and M3v morphologie features. We also correlated CD2 expression status with FAB subtype and CD34 expression. Aberrant expression of CD2 on leukemic promyelocytes previously has been associated with M3v morphologie features. 24 - 25 We found CD2 expression in 8 of 16 APLs, but only 4 of thèse were M3v. On the other hand, our data suggest an association between expression of CD2 and CD34 in that CD2 was coexpressed on 6 (86%) of 7 CD34+ APLs but on only 2 (20%) of 10 CD34 APLs. The relationship among CD34 expression, CD2 expression, and M3v morphologie features needs to be confirmed in a larger séries.
CD34 Status and Response to Therapy
Clinical data were available for 11 of the 17 patients. Patients were divided into 4 groups based on the CD34 status of their leukemias and whether they received ATRA therapy during induction with conventional chemotherapy. Time to response was measured by number of days to achieve a normal bone marrow or days to a CBC count meeting spécifie criteria (platelet count, > 100 x 
Discussion
In the présent study, we demonstrated the présence of a significant subset of CD34 + leukemic cells in 7 (41%) of 17 cases of APL; the majority of leukemic cells were CD34 + in 2 cases (12% 27 Interestingly, our data suggest an association between CD34 expression and M3v. The fact, then, that a significant proportion of our cases hâve CD34 positivity may reflect in part a higher percentage of M3v cases (7/17) in our cohort than in those described in previous studies.
The immunologie and morphologie variability in phenotype between tumors demonstrated in the présent séries, in conjunction with the détermination of very early progenitor cell involvement in 2 cases, raises questions about the biology of APL development and progression. One model for APL development is that the cell of origin is variable and that features spécifie to the cell of origin dictate the phenotype of the tumor. Turhan et al 28 An alternative model for APL development is that the cell of origin is the same for ail tumors and that the phenotypic and morphologie variability dérives from genetic or epigenetic factors that détermine the level of differentiation of individual tumors. The récent observation that the type of PML-RARA fusion (dictated by the PML breakpoint) correlates with the présence or absence of myeloblasts 29 supports this model. Factors that control the particular myeloid pro-
• Tumor évolution also may hâve a rôle in phenotypic variability. In transgenic mouse models, the PML-RARA fusion protein has been shown to recapitulate the phenotype of APL by generating, first, preleukemic and, later, overtly leukemic states, 31 supporting the hypothesis that tumor progression has a rôle in the development of overt leukemia and that the PML-RARA fusion product may be necessary but not sufficient for development of the full leukemic phenotype. Analogous to the situation in other forms of acute leukemia, 32 tumor progression also may hâve a rôle in generating a more genetically evolved lésion. The fact that the CD34 + cases are less differentiated immunophenotypically and morphologically (M3v morphologie features) raises the possibility that thèse cases represent more genetically evolved forms of APL. Corrélation among morphologie features, immunophenotype, and cytogenetic findings in a larger séries might be helpful for addressing this issue.
The récognition that a subset of APLs express CD34 will aid in proper diagnosis and initiation of treatment in thèse cases. Large-scale studies are needed to détermine the effect of this phenotype on ability to achieve complète remission and whether there are long-tenn effects on survival. 
